Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.

ABSTRACT:

Objectives

The 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR TKI) osimertinib has shown promising efficacy both in EGFR-mutant, T790M positive non-small cell lung cancer (NSCLC) patients who have become resistant to 1st or 2nd generation EGFR TKIs and patients with sensitizing EGFR mutations as the first line therapy. However, the degree and duration of response to osimertinib are heterogeneous. We hypothesized that the concurrent genomic landscape of these tumors could play a role in clinical outcomes and/or mechanisms of resistance.

Materials and methods

We conducted a retrospective multicenter study of lung cancer patients who had developed resistance to osimertinib. Genomic profiling was done for all the patients by using targeted next-g

SUBMITTER: Zhao J 

PROVIDER: S-EPMC7961300 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature